OBOYLE KEVIN C 4

What Happened
Kevin O'Boyle, a director of Carlsmed, Inc. (CARL), was granted 13,698 restricted stock units (RSUs) on June 3, 2026. The RSUs were awarded at a $0.00 acquisition price (no immediate cash cost or sale proceeds). The grant is compensation — not an open-market purchase or sale — and does not represent immediately owned shares until the RSUs vest and convert to common stock.

Key Details

• Transaction date: 2026-06-03. Grant type: Award/Grant (RSUs). Report filed 2026-06-22.
• Number of RSUs granted: 13,698. Reported acquisition price: $0.00 (total reported value $0 at grant).
• Vesting: RSUs vest in full on the earlier of (i) the day before the issuer’s 2027 annual meeting of stockholders or (ii) June 3, 2027, subject to O'Boyle’s continued service on the Board through the vesting date. Each RSU converts to one share upon vesting.
• Shares owned after transaction: not specified in the provided excerpt — check the full Form 4 for post-transaction holdings.
• Filing timeliness: the filing date is June 22, 2026, which is more than two business days after the transaction date; this may be a late Form 4 filing.

Context
RSU awards are common as director or executive compensation and do not necessarily signal a near-term market view since they vest over time and depend on continued service. There is no immediate economic benefit until the RSUs vest and convert to shares (unless the company provides other rights, which are not indicated here).